Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

NCT05493709 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Puberty; Precocious, Central

Interventions

DRUG: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide

Sponsor

Foresee Pharmaceuticals Co., Ltd.

Collaborators

[object Object]
[object Object]